MTOR and ovarian cancer: Compound 114, which differs from 115 by an additional glycone at the C-28 position, induces apoptosis in a caspase-independent manner via blocking of significant pathways like mammalian target of rapamycin (mTOR) and mitogen-activated protein kinase (MAPK) in human ovarian cancer cells at 94.87 μM [145].